To confirm the correlation between TSC2 and CD8+ T cell as the TIMER 2.0 revealed, we performed immunohistochemistry (IHC) in the TMA of 164 patients with NSCLC and found that TSC2–low expression tumors also exhibited remarkable increases in CD8A (P < 0.05; Fig. 4, C and D). Here, CD8A is linked to non-small cell lung carcinoma.